179 related articles for article (PubMed ID: 24173498)
1. Evaluation of the expression of stem cell markers in human breast cancer reveals a correlation with clinical progression and metastatic disease in ductal carcinoma.
Martin TA; Jiang WG
Oncol Rep; 2014 Jan; 31(1):262-72. PubMed ID: 24173498
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological Significance of CD133 and ALDH1 Cancer Stem Cell Marker Expression in Invasive Ductal Breast Carcinoma.
Mansour SF; Atwa MM
Asian Pac J Cancer Prev; 2015; 16(17):7491-6. PubMed ID: 26625750
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis.
Han Z; Chen Z; Zheng R; Cheng Z; Gong X; Wang D
World J Surg Oncol; 2015 Feb; 13():56. PubMed ID: 25889325
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas.
Liu Q; Li JG; Zheng XY; Jin F; Dong HT
Chin Med J (Engl); 2009 Nov; 122(22):2763-9. PubMed ID: 19951611
[TBL] [Abstract][Full Text] [Related]
6. Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells.
Lin WM; Karsten U; Goletz S; Cheng RC; Cao Y
Int J Exp Pathol; 2011 Apr; 92(2):97-105. PubMed ID: 21070402
[TBL] [Abstract][Full Text] [Related]
7. Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer.
Nagata T; Sakakura C; Komiyama S; Miyashita A; Nishio M; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Ikoma H; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Kokuba Y; Sonoyama T; Otsuji E
Anticancer Res; 2011 Feb; 31(2):495-500. PubMed ID: 21378329
[TBL] [Abstract][Full Text] [Related]
8. CD133 expressionand clinicopathologic significance in benign and malignant breast lesions.
Liu TT; Li XF; Wang L; Yang JL
Cancer Biomark; 2020; 28(3):293-299. PubMed ID: 32390595
[TBL] [Abstract][Full Text] [Related]
9. Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Sansone P; Ceccarelli C; Berishaj M; Chang Q; Rajasekhar VK; Perna F; Bowman RL; Vidone M; Daly L; Nnoli J; Santini D; Taffurelli M; Shih NN; Feldman M; Mao JJ; Colameco C; Chen J; DeMichele A; Fabbri N; Healey JH; Cricca M; Gasparre G; Lyden D; Bonafé M; Bromberg J
Nat Commun; 2016 Feb; 7():10442. PubMed ID: 26858125
[TBL] [Abstract][Full Text] [Related]
10. Cancer Stem Cell Markers in Eyelid Sebaceous Gland Carcinoma: High Expression of ALDH1, CD133, and ABCG2 Correlates With Poor Prognosis.
Kim N; Choung HK; Lee MJ; Khwarg SI; Kim JE
Invest Ophthalmol Vis Sci; 2015 Feb; 56(3):1813-9. PubMed ID: 25711631
[TBL] [Abstract][Full Text] [Related]
11. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.
Zhao P; Lu Y; Jiang X; Li X
Cancer Sci; 2011 May; 102(5):1107-11. PubMed ID: 21276138
[TBL] [Abstract][Full Text] [Related]
13. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency.
Atkinson RL; Yang WT; Rosen DG; Landis MD; Wong H; Lewis MT; Creighton CJ; Sexton KR; Hilsenbeck SG; Sahin AA; Brewster AM; Woodward WA; Chang JC
Breast Cancer Res; 2013; 15(5):R77. PubMed ID: 24008095
[TBL] [Abstract][Full Text] [Related]
14. The probable role of tumor stem cells for lymph node metastasis in supraglottic carcinoma.
Lu S; Tian J; Lv Z; Wang H; Bai X; Liu W; Li J; Xu W
Pathol Oncol Res; 2011 Mar; 17(1):33-8. PubMed ID: 20407935
[TBL] [Abstract][Full Text] [Related]
15. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas.
Li F; Zeng H; Ying K
Med Oncol; 2011 Dec; 28(4):1458-62. PubMed ID: 20717756
[TBL] [Abstract][Full Text] [Related]
16. Gli1 is a potential cancer stem cell marker and predicts poor prognosis in ductal breast carcinoma.
Ni W; Yang Z; Qi W; Cui C; Cui Y; Xuan Y
Hum Pathol; 2017 Nov; 69():38-45. PubMed ID: 28965964
[TBL] [Abstract][Full Text] [Related]
17. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer.
Wakamatsu Y; Sakamoto N; Oo HZ; Naito Y; Uraoka N; Anami K; Sentani K; Oue N; Yasui W
Pathol Int; 2012 Feb; 62(2):112-9. PubMed ID: 22243781
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.
Kagara N; Huynh KT; Kuo C; Okano H; Sim MS; Elashoff D; Chong K; Giuliano AE; Hoon DS
Am J Pathol; 2012 Jul; 181(1):257-67. PubMed ID: 22626806
[TBL] [Abstract][Full Text] [Related]
19. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.
DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C
Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Wang Z; Shi Q; Wang Z; Gu Y; Shen Y; Sun M; Deng M; Zhang H; Fang J; Zhang S; Xie F
Pathol Res Pract; 2011 Aug; 207(8):505-13. PubMed ID: 21802218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
